Additionally, combining PP2A activators or CIP2A inhibitors with kinase inhibitors (e.g., MEK inhibitors) or chemotherapy enhances anticancer effects, particularly in aggressive cancers like lung cancer [143]. This evidence concerns the gene CIP2A and lung cancer.